EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) today announced that it will host its 1st Annual Biotech Summit on Tuesday, May 16, 2017 at its headquarters in Emeryville detailing for partners, customers and investors how industrial biotech is disrupting high growth markets. The company plans to videocast a portion of the event, including formal presentations and panel discussions, starting at approximately 12:00 p.m. Eastern Time and concluding at approximately 2:00 p.m. Eastern Time.
During the Investor Day portion of the event, the company will review details related to its revenue plans, product and market performance and detail its customer and partner relationships. This will include an update regarding the expected accretive contribution to revenue from the DSM relationship announced yesterday. This will also include a detailed review of the successful partnership with Nenter for Vitamin E and the record growth in Biossance product sales. The company will detail the planned use of proceeds from the majority of the funds expected from the recently announced funding applied to support its strong growth.
Following these sessions, onsite attendees will then participate in an exclusive look into Amyris's labs hosted by members of the company's senior research & development team followed by a networking lunch.
A live videocast of the event will be available online on the Amyris website. To access the live videocast, please visit: http://investors.amyris.com. A replay of the videocast will be available on the Investor Relations section of the Company's website approximately two hours after the conclusion of the presentations and panel discussions.
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected impact from the recently announced relationship with DSM and the anticipated closing of a recently announced financing transaction) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris's Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 firstname.lastname@example.org email@example.com